Protection against Omicron conferred by mRNA primary vaccine series, boosters, and prior infection

ABSTRACT B ackground Prisons and jails are high-risk settings for Covid-19 transmission, morbidity, and mortality. We evaluate protection conferred by prior infection and vaccination against the SARS-CoV-2 Omicron variant within the California state prison system. M ethods We employed a test-negative design to match resident and staff cases during the Omicron wave (December 24, 2021—April 14, 2022) to controls according to a case’s test-week as well as demographic, clinical, and carceral characteristics. We estimated protection against infection using conditional logistic regression, with exposure status defined by vaccination, stratified by number of mRNA doses received, and prior infection, stratified by periods before or during Delta variant predominance. R esults We matched 15,783 resident and 8,539 staff cases to 180,169 resident and 90,409 staff controls. Among cases, 29.7% and 2.2% were infected before or during the emergence of the Delta variant, respectively; 30.6% and 36.3% were vaccinated with two or three doses, respectively. Estimated protection from Omicron infection for two and three doses were 14.9% (95% Confidence Interval [CI], 12.3—19.7%) and 43.2% (42.2—47.4%) for those without known prior infections, 47.8% (95% CI, 46.6—52.8%) and 61.3% (95% CI, 60.7—64.8%) for those infected before the emergence of Delta, and 73.1% (95% CI, 69.8—80.1%) and 86.8% (95% CI, 82.1—92.7) for those infected during the period of Delta predominance. C onclusion A third mRNA dose provided significant, additional protection over two doses, including among individuals with prior infection. Our findings suggest that vaccination should remain a priority—even in settings with high levels of transmission and prior infection.